NCT02724501|Completed
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer
Clinical and Molecular Studies of the Tumour Suppressor Gene PTEN in Endometrioid Type Endometrial Cancer
Loading search results
Clinical and Molecular Studies of the Tumour Suppressor Gene PTEN in Endometrioid Type Endometrial Cancer
Sponsor study identifier
Secondary identifiers
observational
217
1 country
1
Study Start
April 2000
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2011
Actual (reported)Study Completion
October 2011
Actual (reported)This project seeks to understand the role of the PTEN tumour suppressor gene in endometrial cancer (tumours of the uterine lining), the most common gynecologic cancer in the developed world. The studies in this program span the spectrum from fruit flies to humans, as part of a synergistic partnership that will significantly enhance our understanding of the molecular genetic events involved in the development and progression of endometrial cancer. The discovery of new targets for therapy, and the ability to evaluate these in subsequent clinical trials is a significant strength of this scientific interaction, which may result in cures for patients with primary and relapse endometrial cancer and prevention of this cancer in women who are at high risk.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2011
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2000
Date type not reportedThis date has not been verified as actual or estimated.
February 11, 2011
Actual (reported)October 2011
Actual (reported)October 2011
Actual (reported)March 31, 2016
Actual (reported)Number of endometrial cancer patients with inactivated PTEN tumor suppressor gene
Determining the association of PTEN inactivation and PKB expression, mutation of p53, microsatellite instability and progesterone receptor status in endometrial cancer
6 months
Using questionnaire to obtain patient's medical and family history of cancer.
Using Samples obtained to produce summary statistics on the tumour markers
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with Endometrial Cancer
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Anthony Fyles, MD
Princess Margaret Hospital, Canada
217 participants (actual enrollment reported by the registry).
First Submitted
February 11, 2011
First Posted
March 31, 2016
Study Start
April 2000
Date type not reportedThis date has not been verified as actual or estimated.
The Role of POLE Mutation in High Risk Endometrial Cancer.
Contact the study team to confirm eligibility.
Primary Completion
October 2011
Actual (reported)Study Completion
October 2011
Actual (reported)Last Updated
March 31, 2016
Record last verified: 2016-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: